In Brief This Week: Danaher; ACGT, CAP; Thermo Fisher; Quest, CDC; Cleveland Clinic Labs, ACL Labs; More | GenomeWeb

NEW YORK (GenomeWeb News) – Danaher said this week that it anticipates its second-quarter diluted net earnings per share to be "slightly above" the high end of its previously announced guidance of between $.80 and $.85. Core revenue growth, it added is expected to also be "slightly above" the previous guidance of between 1 percent and 2 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.